Kelly CRISPR & Gene Editing Technology ETF Rating → Gold Set to EXPLODE! (From Gold Safe Exchange) (Ad) Free XDNA Stock Alerts $7.38 0.00 (0.00%) (As of 05/10/2024 ET) Add Compare Share Share RatingsStock AnalysisChartHeadlinesHoldingsOptions ChainRatingsShort InterestSocial MediaStock AnalysisChartHeadlinesHoldingsOptions ChainRatingsShort InterestSocial Media Kelly CRISPR & Gene Editing Technology ETF Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.XDNA Aggregate RatingModerate Buy2.61Holdings in XDNA have an aggregate rating of Moderate Buy based on 270 analyst ratings issued in the past year covering 21 companies (94.6% of the portfolio).XDNA Aggregate Price Target$23.38216.77% UpsideHigh Prediction$36.34Average Prediction$23.38Low Prediction$11.01Holdings in XDNA have an aggregate price target of $23.38 and a range of $11.01 to $36.34 covering 21 companies (94.6% of the portfolio).XDNA Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy2 Buy rating(s)Moderate Buy13 Moderate Buy rating(s)Hold6 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Kelly CRISPR & Gene Editing Technology ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 21 XDNA Holdings Export to ExcelWeightIn ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings11.05%NTLAIntellia Therapeutics$24.46-1.6%4 of 5 stars2.69$66.77 173.0%13Analyst ForecastNews Coverage10.70%TMOThermo Fisher Scientific$593.03+2.6%5 of 5 stars2.71$607.35 2.4%179.57%BEAMBeam Therapeutics$21.26-5.7%1 of 5 stars2.38$40.18 89.0%13Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews Coverage8.64%CRSPCRISPR Therapeutics$51.17-4.4%3 of 5 stars2.35$73.93 44.5%17Earnings ReportUpcoming EarningsAnalyst ForecastAnalyst RevisionNews Coverage6.78%CRBUCaribou Biosciences$3.54-3.0%2 of 5 stars2.75$22.50 535.6%4Short Interest ↓Analyst RevisionNews Coverage5.63%VERVVerve Therapeutics$6.01-5.5%3 of 5 stars2.75$33.00 449.1%8Earnings ReportAnalyst ForecastAnalyst RevisionNews Coverage5.16%SGMOSangamo Therapeutics$0.56+7.7%1 of 5 stars2.50$5.67 909.4%6Earnings ReportNews CoverageHigh Trading Volume4.73%PRMEPrime Medicine$5.61-1.9%4 of 5 stars2.73$16.70 197.7%11Analyst ForecastNews CoverageGap Up4.37%ABBVAbbVie$160.75+0.2%4 of 5 stars2.77$174.31 8.4%13Earnings ReportShort Interest ↑4.13%EDITEditas Medicine$5.32-4.3%3 of 5 stars2.50$13.90 161.3%10Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews Coverage4.10%ALLOAllogene Therapeutics$2.76-3.5%2 of 5 stars2.71$13.50 389.1%7Upcoming EarningsShort Interest ↑3.32%PSTXPoseida Therapeutics$2.65-2.2%3 of 5 stars3.00$14.67 454.5%3Upcoming EarningsShort Interest ↑2.96%DTILPrecision BioSciences$10.64-2.7%4 of 5 stars3.00$46.33 335.5%3Upcoming EarningsPositive News2.87%TSVT2seventy bio$4.38-1.1%2 of 5 stars2.44$12.86 193.5%9Analyst ForecastAnalyst RevisionNews Coverage2.40%AAgilent Technologies$149.76+3.2%5 of 5 stars2.59$141.29 -5.7%17Short Interest ↑Analyst Revision2.10%BMYBristol-Myers Squibb$44.94+0.4%5 of 5 stars2.11$60.00 33.5%19Short Interest ↓Analyst Revision2.00%ILMNIllumina$110.53-0.7%5 of 5 stars2.30$164.65 49.0%20Analyst ForecastShort Interest ↓1.53%VRTXVertex Pharmaceuticals$422.78+0.9%4 of 5 stars2.48$432.18 2.2%25Earnings ReportAnalyst Forecast1.29%REGNRegeneron Pharmaceuticals$973.80+0.6%4 of 5 stars2.70$981.71 0.8%20Positive News0.69%QGENQiagen$43.61+0.1%4 of 5 stars2.56$50.95 16.8%90.57%BIIBBiogen$221.50-0.6%5 of 5 stars2.65$288.46 30.2%26Positive News This page (NASDAQ:XDNA) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsObama’s Forever Term [exposed]Porter & CompanyMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kelly CRISPR & Gene Editing Technology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
